Published in J Hepatol on March 12, 2009
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 0.79
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Management of HCC. J Hepatol (2012) 3.03
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology (2010) 2.61
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology (2009) 2.10
Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol (2007) 1.95
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology (2009) 1.70
Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg (2012) 1.70
Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53
Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology (2011) 1.52
Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol (2012) 1.37
Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg (2004) 1.36
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology (2013) 1.19
Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. Ann Surg (2015) 1.17
Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
Transarterial therapies in HCC: does embolization increase survival? J Hepatol (2009) 1.10
Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc (2012) 1.09
Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery (2007) 1.07
Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. J Hepatobiliary Pancreat Surg (2002) 1.03
Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol (2012) 1.02
Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02
Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. Am J Surg (2008) 1.02
Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg (2014) 0.99
How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol (2005) 0.97
Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis (2005) 0.94
Liver transplantation for neuroendocrine tumors. J Gastrointest Surg (2004) 0.93
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91
Treatment of early hepatocellular carcinoma: Towards personalized therapy. Dig Liver Dis (2010) 0.91
Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl (2005) 0.90
Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review. Pediatr Transplant (2015) 0.88
Multifocal hepatocellular carcinoma and precancerous lesions in a patient with autoimmune hepatitis-related cirrhosis. Semin Liver Dis (2008) 0.88
Resection of hepatocellular carcinoma without cirrhosis. Ann Surg (2012) 0.87
Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann Surg Oncol (2008) 0.86
Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging (2011) 0.86
Retracted Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology (2010) 0.86
Giant hemangioma of the adrenal. Isr Med Assoc J (2004) 0.85
New drugs for the treatment of hepatocellular carcinoma. Liver Int (2009) 0.85
Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB (Oxford) (2013) 0.84
Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol (2013) 0.84
Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms. Am J Surg Pathol (2012) 0.83
Marked Differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation (2005) 0.83
Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective. J Hepatobiliary Pancreat Sci (2009) 0.83
Ablation for hepatocellular carcinoma: Is there need to have a winning technique? J Hepatol (2010) 0.82
Consensus report of the Fifth International Forum for Liver MRI. AJR Am J Roentgenol (2013) 0.82
Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2010) 0.82
Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care. Hepatology (2008) 0.82
Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl (2005) 0.82
Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl (2006) 0.82
The role of fibrin sealants in hepatic surgery. Surg Technol Int (2007) 0.81
The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer (2014) 0.81
Diaphragmatic hernia after hepatic resection: case series at a single Western institution. J Gastrointest Surg (2012) 0.81
What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Liver Transpl (2011) 0.80
Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. Radiology (2015) 0.80
Diagnosis and staging of hepatocellular carcinoma prior to transplantation: expertise or failure. Liver Transpl (2006) 0.79
Multiple endocrine neoplasia type 1 associated with a new mutation in the menin gene and a midgut neuroendocrine tumor. Pancreas (2014) 0.79
Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology (2015) 0.79
FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med (2007) 0.79
Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis. J Am Coll Surg (2003) 0.78
Surgical resection for advanced gallbladder carcinoma. The Mount Sinai experience. Hepatogastroenterology (2011) 0.78
Non-invasive diagnostic criteria for hepatocellular carcinoma: the value of contrast washout at imaging and the death of alpha-fetoprotein. Liver Int (2011) 0.77
Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis (2008) 0.77
Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. HPB (Oxford) (2012) 0.77
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. Gastroenterol Hepatol (2010) 0.77
Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol (2013) 0.77
Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. AJR Am J Roentgenol (2013) 0.77
Functional abdominal complaints occurred frequently in living liver donors after donation. Scand J Gastroenterol (2010) 0.76
To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer? Gastroenterology (2009) 0.76
A two-step right hepatic lobectomy with portal vein ligation for large hepatocellular carcinoma: rapid induction of left-lobe regeneration and clinicopathologic correlation. Semin Liver Dis (2013) 0.76
Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience. Int J Surg Oncol (2012) 0.76
Reply:. Hepatology (2013) 0.75
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. Pancreas (2016) 0.75
Recurrent giant hemangiomas of liver: Report of two rare cases with literature review. World J Gastrointest Surg (2012) 0.75
Sunitinib and the benefits of a negative study. Lancet Oncol (2009) 0.75
Expansion of criteria for transplanting patients with hepatocellular carcinoma. Liver Transpl (2008) 0.75
Calcified telangiectatic hyperplastic nodule associated with vascular malformation in a child: a case report. Fetal Pediatr Pathol (2014) 0.75
Renal artery thrombosis following secondary cytoreduction in a patient with ovarian cancer. Gynecol Oncol (2007) 0.75
[Imaging techniques in hepatocellular carcinoma: diagnosis, extension and evaluation of therapeutic response]. Gastroenterol Hepatol (2010) 0.75
Metzenbaum-assisted liver resection: a safe and effective liver resection technique. Dig Surg (2014) 0.75
A 48-year-old obese man with a 3 cm liver lesion and a history of hemochromatosis and lymphoma. Semin Liver Dis (2004) 0.75